- Title
- Phase I / II trial of dose adjusted EPOCH chemotherapy with bortezomib combined with integrase inhibitor therapy for HTLV-1 associated T-cell leukemia lymphoma
- Creators
- Lee Ratner - Division of Oncology, Washington University, St Louis, MO, USAJ C Ramos - University of Miami, Miami, FL, USAAriela Noy - Lymphoma & Hematology Division, Memorial Sloan Kettering Cancer Center, New York, NY, USAStefan Barta - Divisions of Hematology-Oncology, Montefiore Hospital, New York, NY, USASamir Parikh - Divisions of Hematology-Oncology, Montefiore Hospital, New York, NY, USAAdrienne Phillips - Columbia University, New York, NY, USARichard Ambinder - Division of Hematologic Malignancies, Johns Hopkins University, Baltimore, MD, USADan Rauch - Division of Oncology, Washington University, St Louis, MO, USAJohn Harding - Division of Oncology, Washington University, St Louis, MO, USAHicham Baydoun - Division of Oncology, Washington University, St Louis, MO, USAXiaogang Cheng - Division of Oncology, Washington University, St Louis, MO, USABreanna Caruso - NINDS, NIH, Bethesda, MD, USASteven Jacobson - NINDS, NIH, Bethesda, MD, USA
- Publication Details
- Retrovirology, Vol.12(Suppl 1), pp.P21-P21
- Publisher
- BioMed Central
- Academic Unit
- Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
- Language
- English
- Resource Type
- Journal article
- PMCID
- PMC4578736
- Record Identifier
- 991031597995202976
Journal article
Phase I / II trial of dose adjusted EPOCH chemotherapy with bortezomib combined with integrase inhibitor therapy for HTLV-1 associated T-cell leukemia lymphoma
Retrovirology, Vol.12(Suppl 1), pp.P21-P21
2015-08-28
PMCID: PMC4578736
Metrics
26 Record Views
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites